

FOOD AND DRUG ADMINISTRATION

8704 '98 SEP 18 A9:50

Joint Meeting of the
HEMATOLOGY AND PATHOLOGY DEVICES PANEL
and the
IMMUNOLOGY DEVICES PANEL

September 4, 1998
9200 Corporate Blvd.
Rockville, Md.

CASET Associates, Ltd.
10201 Lee Highway
Fairfax, Virginia 22030

PARTICIPANTS

Chairperson: Timothy J. O'Leary, MD, PhD

Executive Secretary: Veronica J. Calvin, MA

Voting Members

Diane D. Davey, MD

Juan C. Felix, MD

Henry A. Homburger, MD

Glen L. Hortin, MD, PhD

Mary M. Kemeny, MD

Charles T. Ladoulis, MD

Carole B. Miller, MD

Consumer Representative

Ellen Rosenthal, MS

Industry Representative

Alton D. Floyd, PhD

CONTENTS

	<u>PAGE</u>
Opening Remarks - Introduction	1
Open Public Hearing	5
FDA Presentation	
Peter Maxim, PhD Chief, Immunology, Hematology and Pathology Branch Division of Clinical Laboratory Devices Office of Device Evaluation, CDRH	6
Julia Goldstein, MD Scientific Reviewer, Div. of Monoclonal Antibodies Office of Therapeutic Research and Review, CBER	8
Sponsor Presentation	
Gretchen M. Murray, PhD Regulatory Affairs Manager, DAKO Corporation, USA	14
Robert Cohen, MD Senior Director, Product Development, Herceptin Project Team Leader, Genentech, Inc.	17 41
Mads Roepke, PhD Research Scientist, DAKO A/S, Denmark	22
FDA Presentation	
Susan Jerian, MD Medical Officer, Div. of Clinical Trial Design & Analysis Office of Therapeutic Research and Review, CBER	95
Nina Chace, M.S. Scientific Reviewer, Immunology, Hematology, and Pathology Branch, Division of Clinical Laboratory Devices, Office of Device Evaluation, CDRH	118
Open Committee Discussion	141
Panel Vote and Recommendations to FDA	194